Making clinical-grade monitoring available at-home and at scale
Creators of home-based clinical monitoring technology, Seer has today made its debut on the Fast Starters 2021 list, recognising its position as one of the fastest growing companies in Australia as chosen by The Australian Financial Review.
In under five years since launch, Seer has helped over 10,000 Australians access life-saving brain and heart monitoring from the comfort of their homes.
“Seer was founded to empower people to take greater control of their health by making clinical-grade monitoring more accessible. Today, Seer is Australia’s largest provider of epilepsy monitoring services,” says Seer CEO & co-founder Dr Dean Freestone.
“It is a privilege to be named amongst other leading companies this year, many of which are committed to harnessing technology to solve problems of immense scale. I’m extremely proud of the Seer team and humbled by the trust and support of our patients, referrers and collaborative partners.”
Rapid growth, global ambitions
Today, Seer provides three times more epilepsy monitoring services than the Australian hospital system combined. More than 20 Seer Medical clinics now operate around the country, allowing patients to be set up for home-based monitoring and bringing clinical-grade care to people in need all around Australia. Seer’s patented home-based, long term video-EEG technology also delivers a diagnostic yield that is 30 times more effective than current routine tests in other clinics.
“Seer’s patented wearables, mobile app, cloud and machine learning technologies enable us to rapidly scale service delivery while reducing the costs of long-term monitoring. This has the potential for exponential productivity and health gains – globally,” explains Dr Freestone.
Seer has seen 35% employment growth throughout 2021, now employing over 185 staff. Approximately half the team is focused on clinical service delivery, with the remaining staff focused on research and development and curating a pipeline of innovative products and services that will enable Seer to revolutionise epilepsy monitoring and management globally.
“We believe timely, accessible healthcare is a universal right. 2022 will be a turning point for Seer as we expand our footprint to provide our life-saving tools to more Australians and to markets beyond our shores.”
“The healthcare sector has undergone widespread disruption and rapid transformation in the past 2 years. It’s very encouraging to see a number of Australian companies at the forefront of these changes,” says Dr Freestone.
“Now more than ever, we want to break down bottlenecks in the system so people can have greater access to essential services. The team at Seer is working tirelessly to improve access to clinical monitoring in a way that reduces the burden on our critical infrastructure – leaving hospital beds available for the people who need them most.”
